Principles of nanoparticle design for overcoming biological barriers to drug delivery
暂无分享,去创建一个
[1] M Ferrari,et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. , 2008, Journal of biomechanics.
[2] Warren C W Chan,et al. Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.
[3] P. Swaan,et al. Endocytic mechanisms for targeted drug delivery. , 2007, Advanced drug delivery reviews.
[4] Moghimi,et al. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. , 1998, Advanced drug delivery reviews.
[5] M. Hetzer,et al. Nuclear envelope formation by chromatin-mediated reorganization of the endoplasmic reticulum , 2007, Nature Cell Biology.
[6] J. Dobson,et al. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery , 2006, Gene Therapy.
[7] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[8] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[9] Wolfgang J Parak,et al. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. , 2009, Nature nanotechnology.
[10] H. Daniel Ou-Yang,et al. The influence of size, shape and vessel geometry on nanoparticle distribution , 2013, Microfluidics and nanofluidics.
[11] W. Mark Saltzman,et al. Synthetic DNA delivery systems , 2000, Nature Biotechnology.
[12] C. Miller,et al. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.
[13] Xiaoyang Xu,et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.
[14] Y. Sugiyama,et al. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[15] Ronnie H. Fang,et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.
[16] Mauro Ferrari,et al. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.
[17] R. Jain,et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.
[18] Dennis E Discher,et al. Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .
[19] Alejandro Sosnik,et al. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. , 2013, Advanced drug delivery reviews.
[20] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[21] Leaf Huang,et al. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. , 2009, Biochimica et biophysica acta.
[22] Milan Makale,et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis , 2008, Proceedings of the National Academy of Sciences.
[23] Alexander V Kabanov,et al. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[24] Kinam Park,et al. Facing the truth about nanotechnology in drug delivery. , 2013, ACS nano.
[25] Lei Zhang,et al. Softer zwitterionic nanogels for longer circulation and lower splenic accumulation. , 2012, ACS nano.
[26] A. Sica,et al. Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.
[27] Michael Hawkins,et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Kit S Lam,et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.
[29] Samir Mitragotri,et al. Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[30] J. M. Harris,et al. Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.
[31] Peter Ramge,et al. Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.
[32] Dennis E Discher,et al. Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. , 2009, Molecular pharmaceutics.
[33] Mauro Ferrari,et al. Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.
[34] Chuan Yang,et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. , 2013, Biomaterials.
[35] Tetsuya Osaka,et al. Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells. , 2009, Colloids and surfaces. B, Biointerfaces.
[36] S. Groshen,et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Mauro Ferrari,et al. Tailored porous silicon microparticles: fabrication and properties. , 2010, Chemphyschem : a European journal of chemical physics and physical chemistry.
[38] Mauro Ferrari,et al. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.
[39] X. Wu,et al. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[40] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[41] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[42] Luigi Naldini,et al. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.
[43] Stephanie E. A. Gratton,et al. The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.
[44] Mauro Ferrari,et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.
[45] M. D'Angelo,et al. Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions , 2012, Nature Reviews Molecular Cell Biology.
[46] J. Fletcher,et al. ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.
[47] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[48] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[49] M. Ferrari,et al. XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.
[50] Feng Liu,et al. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. , 2013, ACS nano.
[51] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[52] R K Jain,et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.
[53] Michael J Sailor,et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. , 2009, Small.
[54] Dakrong Pissuwan,et al. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[55] S. Jeffers,et al. Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2 , 2005 .
[56] Jean-Paul Behr,et al. Intracellular delivery of nanometric DNA particles via the folate receptor. , 2002, Bioconjugate chemistry.
[57] William C. Shuey,et al. Generally Recognized As Safe , 1971 .
[58] Mauro Ferrari,et al. XBP 1 Promotes Triple Negative Breast Cancer By Controlling the HIF 1 α Pathway , 2014 .
[59] Patrick Soon-Shiong,et al. Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.
[60] E. Azzopardi,et al. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. , 2013, The Journal of antimicrobial chemotherapy.
[61] Cornelus F. van Nostrum,et al. Covalently cross-linked amphiphilic block copolymer micelles , 2011 .
[62] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[63] Rachel M Levine,et al. Preparation and characterization of liposome-encapsulated plasmid DNA for gene delivery. , 2013, Langmuir : the ACS journal of surfaces and colloids.
[64] Mauro Ferrari,et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. , 2014, Cancer letters.
[65] Arshed A Quyyumi,et al. Endothelial dysfunction, arterial stiffness, and heart failure. , 2012, Journal of the American College of Cardiology.
[66] Stefan Tenzer,et al. Quantitative profiling of the protein coronas that form around nanoparticles , 2014, Nature Protocols.
[67] Mauro Ferrari,et al. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. , 2009, Biomaterials.
[68] Brian Samuels,et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[70] Stephen T. C. Wong,et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling , 2014, Proceedings of the National Academy of Sciences.
[71] V. Venditto,et al. Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.
[72] D. Hanahan,et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. , 1998, The Journal of clinical investigation.
[73] Patrick Couvreur,et al. Stimuli-responsive nanocarriers for drug delivery. , 2013, Nature materials.
[74] Jiwei Cui,et al. Super‐Soft Hydrogel Particles with Tunable Elasticity in a Microfluidic Blood Capillary Model , 2014, Advanced materials.
[75] L Biganzoli,et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[77] Sung Young Park,et al. Synthesis, characterization, antitumor activity of pluronic mimicking copolymer micelles conjugated with doxorubicin via acid-cleavable linkage. , 2008, Bioconjugate chemistry.
[78] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[79] Anne L. van de Ven,et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.
[80] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[81] L. Zhang,et al. Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.
[82] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] Vladimir P Torchilin,et al. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. , 2011, International journal of pharmaceutics.
[84] M. Ferrari,et al. A Theoretical Model for the Margination of Particles within Blood Vessels , 2005, Annals of Biomedical Engineering.
[85] Mauro Ferrari,et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. , 2014, Cancer research.
[86] Filip Braet,et al. Contribution of high‐resolution correlative imaging techniques in the study of the liver sieve in three‐dimensions , 2007, Microscopy research and technique.
[87] Shutao Guo,et al. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy , 2011 .
[88] C. Alexiou,et al. Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.
[89] Xiaogang Pan,et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[90] R. Jain. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[92] J. Lippincott-Schwartz,et al. New roles for endosomes: from vesicular carriers to multi-purpose platforms , 2009, Nature Reviews Molecular Cell Biology.
[93] Gaurav Sahay,et al. Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[94] Mauro Ferrari,et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[95] Kevin Braeckmans,et al. Intracellular delivery of nanomaterials: how to catch endosomal escape in the act , 2014 .
[96] W. Gradishar,et al. Albumin-bound paclitaxel: a next-generation taxane , 2006, Expert opinion on pharmacotherapy.
[97] R. Jain,et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.
[98] H. Maeda,et al. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.
[99] Kanlaya Prapainop,et al. A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. , 2012, Journal of the American Chemical Society.
[100] L. Weiss,et al. The role of the sinus wall in the passage of erythrocytes through the spleen. , 1973, Blood.
[101] Samir Mitragotri,et al. Shape Induced Inhibition of Phagocytosis of Polymer Particles , 2008, Pharmaceutical Research.
[102] Fan Zhang,et al. Highly biocompatible zwitterionic phospholipids coated upconversion nanoparticles for efficient bioimaging. , 2014, Analytical chemistry.
[103] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[104] Jinming Gao,et al. Modeling particle shape-dependent dynamics in nanomedicine. , 2011, Journal of nanoscience and nanotechnology.
[105] Jun Wang,et al. Surface Charge Switchable Nanoparticles Based on Zwitterionic Polymer for Enhanced Drug Delivery to Tumor , 2012, Advanced materials.
[106] F. Geissmann,et al. Monocytes in atherosclerosis: subsets and functions , 2010, Nature Reviews Cardiology.
[107] T. A. Hatton,et al. Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[108] Afsaneh Lavasanifar,et al. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. , 2011, ACS nano.
[109] D. Hoekstra,et al. Cationic lipids, lipoplexes and intracellular delivery of genes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[110] D. Rees,et al. ABC transporters: the power to change , 2009, Nature Reviews Molecular Cell Biology.
[111] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[112] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[113] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[114] Mary E Napier,et al. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[115] Neetu Singh,et al. Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.
[116] Jeffrey L. Wrana,et al. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling , 2005, Nature Reviews Molecular Cell Biology.
[117] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[118] H. O'brodovich,et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer , 1999, Gene Therapy.
[119] P. Choyke,et al. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. , 2008, Nanomedicine.
[120] Xin Cai,et al. Radioactive 198Au-Doped Nanostructures with Different Shapes for In Vivo Analyses of Their Biodistribution, Tumor Uptake, and Intratumoral Distribution , 2014, ACS nano.
[121] V. Rotello,et al. Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles , 2011, PloS one.
[122] D. Discher,et al. Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.
[123] C. Sheridan,et al. Gene therapy finds its niche , 2011, Nature Biotechnology.
[124] Kazunori Kataoka,et al. A protein nanocarrier from charge-conversion polymer in response to endosomal pH. , 2007, Journal of the American Chemical Society.
[125] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.